These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 20019589)

  • 1. Clinical bioequivalence of a dose of clopidogrel Leti Cravid tablets 75 mg versus clopidogrel Sanofi Plavix tablets 75 mg administered on a daily dose for 7 days on healthy volunteers: a clinical trial.
    Müller A; Octavio J; González MY; Contreras J; Méndez G; Portillo M; Valero Z
    Am J Ther; 2010; 17(3):351-6. PubMed ID: 20019589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects.
    Kim SD; Kang W; Lee HW; Park DJ; Ahn JH; Kim MJ; Kim EY; Kim SW; Nam HS; Na HJ; Yoon YR
    Clin Ther; 2009 Apr; 31(4):793-803. PubMed ID: 19446152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study.
    Di Girolamo G; Czerniuk P; Bertuola R; Keller GA
    Clin Ther; 2010 Jan; 32(1):161-70. PubMed ID: 20171421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of effects of two different formulations of clopidogrel bisulfate tablets on platelet aggregation and bleeding time in healthy Korean volunteers: A single-dose, randomized, open-label, 1-week, two-period, phase IV crossover study.
    Shim CY; Park S; Song JW; Lee SH; Kim JS; Chung N
    Clin Ther; 2010 Aug; 32(9):1664-73. PubMed ID: 20974324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
    Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E;
    Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.
    Angiolillo DJ; Bernardo E; Palazuelos J; Desai B; Weisberg I; Alfonso F; Guzman LA; Hernández-Antolin R; Zenni MZ; Macaya C; Fernandez-Ortiz A; Bass TA
    Thromb Haemost; 2008 Jan; 99(1):161-8. PubMed ID: 18217149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.
    Mitsios JV; Papathanasiou AI; Rodis FI; Elisaf M; Goudevenos JA; Tselepis AD
    Circulation; 2004 Mar; 109(11):1335-8. PubMed ID: 15023882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clopidogrel did not inhibit platelet function early after coronary bypass surgery: A prospective randomized trial.
    Lim E; Cornelissen J; Routledge T; Kirtland S; Charman SC; Bellm S; Munday H; Khan O; Masood I; Large S
    J Thorac Cardiovasc Surg; 2004 Sep; 128(3):432-5. PubMed ID: 15354104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects.
    Thebault JJ; Kieffer G; Lowe GD; Nimmo WS; Cariou R
    Semin Thromb Hemost; 1999; 25 Suppl 2():9-14. PubMed ID: 10440416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
    Angiolillo DJ; Shoemaker SB; Desai B; Yuan H; Charlton RK; Bernardo E; Zenni MM; Guzman LA; Bass TA; Costa MA
    Circulation; 2007 Feb; 115(6):708-16. PubMed ID: 17261652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel.
    Gurbel PA; Bliden KP; Fort JG; Jeong YH; Shuldiner A; Chai S; Gesheff T; Antonino M; Gesheff M; Zhang Y; Tantry US
    Am Heart J; 2013 Feb; 165(2):176-82. PubMed ID: 23351820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial.
    von Beckerath N; Taubert D; Pogatsa-Murray G; Schömig E; Kastrati A; Schömig A
    Circulation; 2005 Nov; 112(19):2946-50. PubMed ID: 16260639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
    Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
    Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic and pharmacokinetic evaluation of clopidogrel and the carboxylic acid metabolite SR 26334 in healthy dogs.
    Brainard BM; Kleine SA; Papich MG; Budsberg SC
    Am J Vet Res; 2010 Jul; 71(7):822-30. PubMed ID: 20594086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clopidogrel and drug metabolism: absence of effect on hepatic enzymes in healthy volunteers.
    Pierce CH; Houle JM; Dickinson JP; Kindermans M; Serre-Lacroix E; Kieffer G; Necciari J
    Semin Thromb Hemost; 1999; 25 Suppl 2():35-9. PubMed ID: 10440421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
    James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
    Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects.
    Savcic M; Hauert J; Bachmann F; Wyld PJ; Geudelin B; Cariou R
    Semin Thromb Hemost; 1999; 25 Suppl 2():15-9. PubMed ID: 10440417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial.
    Yong G; Rankin J; Ferguson L; Thom J; French J; Brieger D; Chew DP; Dick R; Eccleston D; Hockings B; Walters D; Whelan A; Eikelboom JW
    Am Heart J; 2009 Jan; 157(1):60.e1-9. PubMed ID: 19081397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose pharmacodynamics of clopidogrel.
    Thebault JJ; Kieffer G; Cariou R
    Semin Thromb Hemost; 1999; 25 Suppl 2():3-8. PubMed ID: 10440415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days.
    von Beckerath N; Kastrati A; Wieczorek A; Pogatsa-Murray G; Sibbing D; Graf I; Schömig A
    Eur Heart J; 2007 Aug; 28(15):1814-9. PubMed ID: 17272357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.